No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Integral Diagnostics Limited operates within the healthcare sector, providing essential diagnostic imaging services. These services are delivered to general practitioners, medical specialists, allied health professionals, and their patients across Australia and New Zealand. The company manages its service delivery through a network of 67 radiology clinics. Integral Diagnostics was incorporated in 2008 and maintains its primary corporate office in Melbourne, Australia.
www.integraldiagnostics.com.auNo one on the platform currently holds IDX.AX.
No tracked institution reports a position in IDX.AX as of their last filing.
No one on the platform has traded IDX.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.8% | — | — | — | ||
| Rev. Growth % | 25.7% | 17.7% | ||||
| Profit Margin % | 2.8% | 0.1% | 4.3% | |||
| Free Cash Flow Margin % | 5.8% | 5.2% | 7.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $839M | +6.0% | $0.13 | $0.13–$0.14 | — | 10 |
| 2028 | $886M | +5.6% | $0.16 | $0.15–$0.19 | — | 11 |
| 2029 | $936M | +5.6% | $0.17 | $0.16–$0.22 | — | 9 |
| 2030 | $1.0B | +7.3% | $0.20 | $0.20–$0.22 | — | 3 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-24 | $0.06 | $0.06 | +1.2% |
| 2026-02-24 | $0.06 | $0.02 | -57.2% |
| 2025-08-25 | $0.06 | $0.07 | +9.7% |
| 2025-02-25 | $0.04 | $0.04 | -7.6% |
| 2024-08-26 | $0.05 | $0.05 | -10.3% |
| 2024-02-19 | $0.03 | $0.03 | -1.5% |
| 2024-01-12 | $0.05 | $0.04 | -11.4% |
| 2023-02-16 | $0.06 |
| $0.03 |
| -41.8% |
| +10.00% |
| $104M |
| — |
| MVF.AXMonash IVF Group Limited | $0.76 | -3.82% | $294M | — |
| NAN.AXNanosonics Limited | $2.84 | +1.43% | $849M | — |
Source: Financial Modeling Prep · peers by sector/industry